Insider Buying: OPKO Health (NASDAQ:OPK) Director Purchases $11,400.00 in Stock

OPKO Health, Inc. (NASDAQ:OPK) Director John Paganelli purchased 10,000 shares of the firm’s stock in a transaction dated Friday, March 20th. The shares were bought at an average price of $1.14 per share, for a total transaction of $11,400.00. Following the completion of the transaction, the director owned 394,340 shares of the company’s stock, valued at approximately $449,547.60. This trade represents a 2.60% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

OPKO Health Stock Down 4.3%

OPK opened at $1.12 on Monday. The company has a fifty day moving average price of $1.23 and a 200-day moving average price of $1.34. The firm has a market capitalization of $850.16 million, a P/E ratio of -3.73 and a beta of 1.50. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.97 and a quick ratio of 3.52. OPKO Health, Inc. has a one year low of $1.10 and a one year high of $1.83.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings data on Thursday, February 26th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03. The company had revenue of $148.50 million for the quarter, compared to the consensus estimate of $139.76 million. OPKO Health had a negative return on equity of 17.42% and a negative net margin of 37.19%.The firm’s revenue was down 19.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.01 earnings per share. Equities research analysts expect that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of OPKO Health in a research report on Thursday, January 22nd. Barrington Research lowered their target price on shares of OPKO Health from $2.25 to $1.50 and set an “outperform” rating on the stock in a research note on Monday, March 2nd. Finally, Wall Street Zen lowered shares of OPKO Health from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $2.03.

Trending Headlines about OPKO Health

Here are the key news stories impacting OPKO Health this week:

• Positive Sentiment: Director John A. Paganelli purchased 10,000 shares at about $1.14, increasing his stake to 394,340 shares — insider buying often signals management confidence and can provide short‑term support. SEC Filing
• Positive Sentiment: Several institutional investors added or initiated positions in Q4 (e.g., World Investment Advisors, Virtu Financial, XTX Topco), indicating some institutional interest that can underpin the share base. MarketBeat Holdings Summary
• Neutral Sentiment: Analysts’ consensus remains a “Hold” rating on OPK (average price target near $2.03) — a mixed broker view that suggests limited near‑term conviction either way. Analyst Ratings Article
• Neutral Sentiment: Zacks published forward earnings commentary (including a FY2028 outlook) that highlights OPKO’s strengths (RAYALDEE sales, partnerships) but also calls out revenue decline and concentration risk — useful context for longer‑term investors. Zacks FY2028 Article
• Negative Sentiment: Zacks Research sharply cut near‑term and multi‑quarter EPS forecasts across Q3/Q4 2026–2027 and lowered FY2026/FY2027 estimates (many quarters now ~$(0.07)–$(0.08); FYs lowered toward ~$(0.29)). These downgrades meaningfully reduce profit expectations and are a primary driver of weaker investor sentiment today. Zacks Estimate Cuts (MarketBeat summary)
• Negative Sentiment: Barrington trimmed its price target from $2.25 to $1.50 (even while maintaining a constructive rating), which lowers the visible upside and can weigh on short‑term trading demand. Barrington PT Cut

Institutional Investors Weigh In On OPKO Health

Several hedge funds have recently added to or reduced their stakes in OPK. World Investment Advisors boosted its holdings in shares of OPKO Health by 63.8% in the 4th quarter. World Investment Advisors now owns 66,520 shares of the biotechnology company’s stock worth $84,000 after purchasing an additional 25,902 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its holdings in shares of OPKO Health by 1,056.9% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 39,232 shares of the biotechnology company’s stock valued at $49,000 after buying an additional 35,841 shares in the last quarter. Virtu Financial LLC bought a new stake in OPKO Health in the 4th quarter worth approximately $145,000. EP Wealth Advisors LLC bought a new stake in OPKO Health in the 4th quarter worth approximately $37,000. Finally, XTX Topco Ltd purchased a new stake in OPKO Health in the fourth quarter worth approximately $432,000. Institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.